Tuesday 25th April 2017
Thursday 20th April 2017
c-Kit Pathway Influences Scleroderma Development
Thursday 20th April 2017
Nailfold Capillaroscopy as a Research Tool
Thursday 20th April 2017
Identifying Life-Threatening Arrhythmias in Scleroderma
Thursday 20th April 2017
Treatment of Bowel Dysfunction in Scleroderma
Friday 24th March 2017
Nailfold Capillaroscopy Research in Raynaud’s
In spring last year SRUK awarded its first research grants, following on from the work of the Raynaud’s and Scleroderma Association and Scleroderma Society, which had been supporting research into both conditions in this way since the 1980s.
Tuesday 7th March 2017
Prescription Charges Coalition Survey
The Prescription Charges Coalition has launched a survey looking at the ways in which prescription charges affect the lives of people in England with long-term conditions such as Scleroderma and Raynaud’s.
Wednesday 22nd February 2017
Scleroderma & Raynaud’s UK online test helps over 3,000 people establish if they have Raynaud’s
Tuesday 13th December 2016
UK Strategy for Rare Diseases
Wednesday 28th September 2016
Nintedanib Receives Orphan Drug Designation for Systemic Sclerosis
The FDA has granted Orphan Drug Designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD). - See more at: http://www.pharmacytimes.com/product-news/nintedanib-receives-orphan-drug-designation-for-systemic-sclerosis#sthash.5ACj39Ga.dpuf